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14 Abstract Chronic spinal cord dysfunction occurs in dogs as a
15 consequence of diverse aetiologies, including long-standing
16 spinal cord compression and insidious neurodegenerative con-
17 ditions. One such neurodegenerative condition is canine degen-
18 erative myelopathy (DM), which clinically is a challenge to
19 differentiate from other chronic spinal cord conditions.
20 Although the clinical diagnosis of DM can be strengthened by
21 the identification of the Sod1 mutations that are observed in
22 affected dogs, genetic analysis alone is insufficient to provide a
23 definitive diagnosis. There is a requirement to identify bio-
24 markers that can differentiate conditions with a similar clinical
25 presentation, thus facilitating patient diagnostic and manage-
26 ment strategies. A comparison of the cerebrospinal fluid (CSF)
27protein gel electrophoresis profile between idiopathic epilepsy
28(IE) and DM identified a protein band that was more prominent
29in DM. This band was subsequently found to contain a multi-
30functional protein clusterin (apolipoprotein J) that is protective
31against endoplasmic reticulum (ER) stress-mediated apoptosis,
32oxidative stress, and also serves as an extracellular chaperone
33influencing protein aggregation. Western blot analysis of CSF
34clusterin confirmed elevated levels in DM compared to IE (p<
350.05). Analysis of spinal cord tissue from DM and control
36material found that clusterin expression was evident in neurons
37and that the clusterin mRNA levels from tissue extracts were
38elevated in DM compared to the control. The plasma clusterin
39levels was comparable between these groups. However, a
40comparison of clusterin CSF levels in a number of neurolog-
41ical conditions found that clusterin was elevated in both DM
42and chronic intervertebral disc disease (cIVDD) but not in
43meningoencephalitis and IE. These findings indicate that
44clusterin may potentially serve as a marker for chronic spinal
45cord disease in the dog; however, additional markers are
46required to differentiate DM from a concurrent condition such
47as cIVDD.
48Keywords Dog . Spinal cord disease . Clusterin .
49Biomarkers . Sod1
50Introduction
51Cerebrospinal fluid (CSF) has been investigated as a potential
52source of biomarkers in a range of human and animal neuro-
53logical disorders (Satoh et al. 2007; Tumani et al. 2008). From
54a veterinary perspective, a number of neurological conditions
55can present similar clinical features and therefore the identifi-
56cation of specific biomarkers would greatly facilitate diagno-
57sis, patient treatment and management strategies. Canine de-
58generative myelopathy (DM) is one such condition that can be
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59 difficult to diagnose clinically. It is a spontaneously occurring,
60 adult-onset, progressive neurodegenerative condition that has
61 been recognised as a clinicopathological entity for many years
62 (Averill 1973; Coates and Wininger 2010). The condition is
63 particularly prevalent in German Shepherd dog (Griffiths and
64 Duncan 1975), however a number of other breeds are also
65 affected, including Pembroke Welsh corgis (March et al.
66 2009), Bernese Mountain dogs (BMD) (Wininger et al.
67 2011) and boxer dogs (Shelton et al. 2012). Dogs with DM
68 have an insidious onset of progressive upper motor neuron
69 paresis and ataxia of the pelvic limbs that ultimately leads to
70 paraplegia/quadriplegia and euthanasia. Affected dogs that are
71 nursed beyond the paraparetic/plegic state eventually manifest
72 lower motor neuron signs (flaccid paralysis and muscle atro-
73 phy) in the pelvic limbs, followed by thoracic limb involve-
74 ment. Urinary incontinence and brainstem signs such as in-
75 ability to bark and swallowing difficulty too have been report-
76 ed in dogs with advanced DM (Coates and Wininger 2010).
77 The principle pathological features of DM are described as a
78 non-inflammatory segmental axonal degeneration and sec-
79 ondary demyelination affecting white matter tracts with the
80 presence of astrocytosis and astrogliosis (Johnston et al.
81 2000). The white matter lesions are most extensively found
82 in the middle to lower thoracic region. Denervation atrophy of
83 muscle and peripheral neuropathy are also described in dogs
84 with advanced DM (Shelton et al. 2012), implying the in-
85 volvement of motor neurons. However, specific changes in
86 spinal cord motor neurons are not evident at the light micro-
87 scopic level (Coates and Wininger 2010). Abnormalities in
88 specific brainstem nuclei including red nucleus have been
89 reported in the brain (Johnston et al. 2000).
90 The clinical presentation of DMmaymimic many acquired
91 spinal cord diseases, some of which can also co-exist with
92 DM, confounding clinical diagnosis. In the early stages of
93 DM, these would most commonly include conditions such as
94 chronic intervertebral disc disease, degenerative lumbosacral
95 syndrome and spinal cord neoplasia (Cherubini et al. 2008).
96 The diagnosis of DM is also complicated by a lack of specific
97 diagnostic tests in the clinical environment which thus relies
98 on the interpretation of case data by the clinician and the
99 necessity of post mortem examination for confirmation. A
100 genetic study has established that the occurrence of DM is
101 strongly associated with a mutation in Sod1 gene (118G>A or
102 E40K) at the same time implying DM is potentially
103 orthologous to human amyotrophic lateral sclerosis (ALS)
104 (Awano et al. 2009). The E40K Sod1 mutation has been
105 recognised as a major risk factor in developing DM, however
106 it does not appear to be specific to DM as the mutation is also
107 seen in a proportion of non-affected individuals and there are
108 rare individuals that do not carry the mutation. In addition, a
109 recent report has identified a novel Sod1mutation (52A>T) in
110 an affected BMD (Wininger et al. 2011), implying there is the
111 potential for the discovery of further Sod1 mutation(s) in DM.
112Although sequencing could be employed to detect known
113mutations and screen for new polymorphisms in man, the
114detection of a polymorphism in the SOD1 gene is not exclu-
115sively synonymous with a clinically significant mutation and
116may not be specifically diagnostic (Felbecker et al. 2010).
117Therefore, additional clinical indices, e.g. protein-based bio-
118markers are required to specifically differentiate DM from
119other neurological diseases in the clinic, as well as provide
120new potential insights into disease mechanisms. The success-
121ful development of DM biomarkers as an adjunct assay,
122complementary to genetic marker(s) and the current diagnos-
123tic methods used in DM, would be of substantial value to
124owners and clinicians.
125The main aim of this study is to establish potential CSF
126biomarkers in dogs that could be used to differentiate between
127chronic spinal conditions and in particular increase the confi-
128dence in the clinical diagnosis of DM. We have previously
129investigated the stability of a number of proteins in canine
130CSF, including an acute phase protein, haptoglobin and a
131multifunctional chaperone protein clusterin (Shafie et al.
1322013). We now report on the potential for these proteins to
133serve as biomarkers for chronic canine spinal cord disorders.
134Materials and methods
135Clinical material
136All dogs included in the CSF biomarker study were presented
137to the Small Animal Hospital at The University of Glasgow
138School of Veterinary Medicine for clinical investigation.
139Ethical approval for the storage and use of CSF samples
140collected as part of such investigations, andwhich were excess
141to the immediate clinical requirements, was granted by the
142School of Veterinary Medicine Ethics andWelfare Committee
143of the University of Glasgow. All dogs received complete
144physical and neurological examination. The neurological ex-
145amination included the assessment of mental alertness, gait,
146posture, cranial nerve function, spinal reflexes and responses
147to stimuli. Magnetic resonance imaging and clinicopatholog-
148ical evaluations comprised of complete blood counts, serum
149biochemistry and CSF analysis were routinely performed in
150all cases. CSF (0.5–1.0 ml) was collected into a sterile tube,
151harvested either from the cerebellomedullary or lumbar cistern
152under general anaesthesia. The majority of samples for CSF
153analyses were collected from cerebellomedullary cistern.
154Whole blood samples were also collected from the jugular
155vein for the purpose of other investigations and an aliquot
156stored for genomic DNA (gDNA) extraction. Post mortem
157examination was not performed in these cases. All clinical
158samples were temporarily stored at −20°C (maximum 3 days)
159before being transported on ice to the laboratory, aliquoted and
160stored at −80°C as has been described previously (Shafie et al.
I.N.F. Shafie et al.
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161 2013). Since obtaining CSF from healthy dogs is not permit-
162 ted on ethical grounds, dogs with idiopathic epilepsy (IE) and
163 with the last seizure >3 days from the time of investigation
164 were selected as controls. Samples were also obtained from
165 dogs affected by meningoencephalitis (MEN), which is a
166 neuroinflammatory disorder, and chronic intervertebral disc
167 disease (cIVDD). Majority of CSF samples for this analysis
168 were collected from cistern magna.
169 A separate archive was utilised for plasma, mRNA and
170 immunohistochemistry (IHC) analyses. Clinical material for
171 these studies was derived from samples collected as part of a
172 study of DM between the period of 1994 and 1998 (Johnston
173 et al. 2000). Plasma was extracted from EDTA-treated blood
174 samples that were stored at −80°C. As part of this study spinal
175 cord and spleen tissue were collected post mortem, snap
176 frozen and stored in liquid nitrogen. IHC analyses were
177 performed using fixed spinal cord tissue. Controls for these
178 analyses were taken from non-neurological cases collected as
179 part of the study by Johnston et al. (2000). CSF was not
180 archived in this study.
181 All cases were subsequently genotyped based on the pres-
182 ence of a 118G>A mutation in the Sod1 gene (Awano et al.
183 2009) using a restriction fragment length polymorphismmeth-
184 od that was developed in-house (Supplementary data). The
185 selection of DM cases for all experiments was based on the
186 clinical diagnosis of DM and homozygosity for the mutant
187 allele in the Sod1 gene.
188 Identification of clusterin and haptoglobin as proteins
189 of interest in canine CSF by liquid chromatography–mass
190 spectrometry
191 Agroup of representative DMand IECSF protein profiles were
192 visualised using Coomassie Blue (SimplyBlue™ SafeStain,
193 Invitrogen, UK) (Fig. 1). The differentially expressed bands
194 were excised for liquid chromatography–mass spectrometry
195 (LC-MS) analysis at the Polyomics facility, University of
196 Glasgow using procedures that have been previously described
197 in detail (Szoor et al. 2013). Protein identifications were
198 assigned using the Mascot search engine (Matrix Science,
199 USA) to interrogate protein sequences in the NCBI Genbank
200 database at 95 % confidence level.
201 SDS-PAGE and Western blot
202 Western blot analysis was performed as previously detailed by
203 (Shafie et al. 2013). In brief, 5 μg of protein from each sample
204 was separated on a 4–12 % Bis–Tris mini gel (NUPAGE
205 Novex, Invitrogen, UK). The samples from each disease
206 condition were loaded alternately across the gel. A CSF sam-
207 ple was aliquoted, stored at −80 °C and included with each gel
208 run to serve as a reference standard (std). Separated proteins
209 were transferred to a nitrocellulose membrane and stained
210with Ponceau S to assess the consistency of protein loading
211between samples. Separated proteins were transferred to a
212nitrocellulose membrane, blocked with 5 % milk powder in
213Tris-buffered saline (TBS) containing 0.1 % Tween-20 (1× T-
214TBS), incubated overnight at 4 °C with polyclonal anti
215clusterin antibody at 1:50,000 dilution (cat. no:ab39991,
216Abcam, UK) or anti haptoglobin antibody (supplied by Prof
217David Eckersall, University of Glasgow) in 5 % powdered
218milk/T-TBS, then with horseradish peroxidise (HRP) conju-
219gated secondary antibody. Immunocomplexes were detected
220using the enhanced chemiluminescence (ECL) reaction
221(Thermo Fisher Scientific, UK) and visualised with radio-
222graphic film (Hyperfilm ECL, Amersham Biosciences, UK).
223Immunocomplexes detected by the ECL reagent was quanti-
224fied by ImageJ (NIH, USA) and the density of protein signal
225was calculated relative to the reference standard and expressed
226as relative abundance.
227For plasma analysis, EDTA-treated blood was available
228from the archive material that had been stored at −80 °C and
229subjected to freeze–thaw cycles which has lead to significant
230haemolysis resulting in a high haemoglobin content which
231would compromise the protein assay. Samples were centri-
232fuged at 5,000×g for 20 min, the supernatant removed and
233subsequently diluted in 1:20 with ultrapure water. A fixed
234volume of 3 μl of diluted sample was processed for SDS-
235PAGE and DM and control samples were loaded alternately
236into the gel. The Western blot procedure was performed as
237described above using the clusterin antibody at a 1:100,000
238dilution. Immunocomplexes quantified for each group using
239ImageJ were calculated relative to the reference standard and
240expressed as relative abundance.
Fig. 1 SDS-PAGE analysis of IE and DM CSF. SDS-PAGE analysis of
IE (n =4) and DM CSF (n=4) followed by Coomassie Blue staining
revealed an additional protein band at approximately 38 kDa, which was
consistently visible in DMCSF (as shown by black arrow), but present at
a lower intensity in the IE cases. The comparatively low densities of
staining in lane 5 may have been due to a loading error.Mkr pre-stained
molecular weight marker, IE idiopathic epilepsy, DM degenerative
myelopathy
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241 Reverse transcriptase polymerase chain reaction
242 RNAwas extracted from the 12th thoracic spinal cord segment
243 (T12) of archival tissue using a commercial kit (AMS
244 Biotechnology, UK). The reverse transcription reaction was
245 performed as described previously (Al-Saktawi et al. 2003) and
246 clusterin cDNAwas amplified using forward (5′-GCCCTTCTT
247 TGA CAT GATACA CCA-3′) and reverse (5′-TGCTTC TGG
248 GAT CAT CAC CGT GA-3′) primers (Eurofins, Germany). A
249 housekeeping gene, cyclophilin was utilised as an internal stan-
250 dard. The primers for cyclophilin and PCR conditions were as
251 described (Montague et al. 1997). The PCR products were
252 resolved on a 2 % agarose gel visualised with ethidium bromide
253 staining and the captured images quantified using ImageJ soft-
254 ware. The intensity of the mRNA signal was corrected relative to
255 the intensity of cyclophilin products.
256 Immunohistochemistry
257 IHC analysis was performed on 4 μm T12 spinal cord sections
258 using Envision+™ System HRP (Dako Cytomation, UK).
259 Sections were initially hydrated and antigen unmasking was
260 performed using 10 mM sodium citrate buffer pH 6.0 in an
261 automated pressure cooker (Menarini Diagnostics, UK). The
262 endogenous peroxidase activity was quenched, followed by the
263 incubation of the primary antibody at a 1:4,000 dilution (cat.
264 no: ab104652, Abcam, UK). Sections were washed and incu-
265 bated with HRP conjugated antibody. The immunocomplexes
266 were detected with 3,3′-diaminobenzidine chromogen.
267 Sections were dehydrated using a series of degraded alcohol
268 baths and mounted in DPX. The primary antibody was omitted
269 to give a negative control. All sections were reviewed blind and
270 the intensity of staining was recorded based on a subjective
271 scoring system.
272 Statistical analysis
273 Statistical analyses were performed using GraphPad Prism
274 version 5.0 (GraphPad Software Inc., USA). The values de-
275 rived fromWestern blots and reverse transcriptase polymerase
276 chain reaction (RT-PCR) were assessed for normality using
277 D’Agostino–Pearson omnibus test. Statistical comparison be-
278 tween the control and treated groups was performed using
279 Mann–WhitneyU or Kruskal–Wallis with a significance level
280 (α ) set at 0.05.
281 Results
282 Statistical assessment of normality distribution
283 All data generated from each group was statistically assessed
284 and failed to meet the requirements of a normal distribution.
285Inclusion/exclusion criteria
286The Sod1 genotyping protocol was developed and optimised
287during the course of this study. Genotyping was not completed
288until after the protein analysis had been performed. For the CSF
289studies, all cases were genotyped for the 118G>A Sod1 muta-
290tion. All DM cases were homozygous for the mutation and had
291a clinical diagnosis. Affected dogs that were heterozygous for
292the Sod1 mutation were excluded from the data analysis
293(marked as H in figures) as these animals did not have a
294confirmatory pathological diagnosis and the inconsistency of
295the development DM in heterozygous animals. Control sam-
296ples for CSF analysis were derived from cases of IE as they
297were demonstrated to be free of spinal cord conditions and/or
298significant neurodegenerative diseases and included animals
299that were either heterozygous or lacking the 118G>A Sod1
300mutation. CSF samples from cases representing other disease
301categories were either heterozygous or lacking the Sod1 muta-
302tion. Cases with acute disease (marked as C), e.g. IE (epileptic
303seizure <3 days prior to sampling) or acute disc disease (<48 h
304prior to sampling) were excluded as DM is a chronic disease.
305Further material from DM cases managed with a history of
306corticosteroid administration was excluded as steroids induce
307haptoglobin expression (Harvey and West 1987).
308For the clusterin plasma level analysis, all cases had a
309clinical diagnosis of DM backed, for those with appropriate
310archived tissues, by pathological confirmation and were ho-
311mozygous for the 118G>A Sod1 mutation. Clusterin mRNA
312expression and IHC were conducted on the archival material.
313All DM cases had a pathologically confirmed clinical diagno-
314sis and were homozygous for the 118G>A Sod1 mutation.
315All control cases were dogs unaffected clinically or patholog-
316ically by DM and lacking the Sod1 mutation.
317Identification of clusterin and haptoglobin as canine CSF
318proteins of interest
319The CSF protein profile differences between IE (n=4) and DM
320(n =4) was visualised using the Coomassie Blue stain and
321revealed a protein band estimated at 38 kDa (indicated by the
322black arrow in Fig. 1) which was consistently present in all DM
323samples and almost undetectable in IE CSF (Fig. 1). This band
324was excised and the protein constituents investigated by LC-
325MS. Two proteins, haptoglobin and clusterin (apolipoprotein J)
326emerged as constituents of the gel band. Validation of the
327presence of these two proteins and their relative expression level
328between the IE and DM groups was then assessed by western
329blot.
330Assessment of haptoglobin and clusterin levels in CSF in DM
331The comparative analysis of haptoglobin found that there was
332no significant difference in the level detected in the DM (n =5)
I.N.F. Shafie et al.
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333 group compared to the IE (n =8) group (Fig. 2). The exclusion
334 criteria described above were applied to appropriate cases. In
335 addition, some samples failed to give a quantifiable signal
336 (marked as X in figures). The comparative analysis of CSF
337 clusterin demonstrated that the level of clusterin was signifi-
338 cantly elevated in the DM (n =7) compared to the IE (n =9)
339 group (p <0.001) (Fig. 3).
340 Assessment of clusterin levels in plasma
341 Plasma clusterin levels were examined to determine if the
342 elevated CSF clusterin levels were a consequence of raised
343 plasma clusterin levels. Western blot analysis of controls
344 (n =8) and DM (n =8) plasma clusterin detected a protein
345 at approximately 38 kDa and similar to the molecular
346 weight of CSF clusterin (data not shown). Statistical
347 analysis comparing controls and DM cases found that
348 there was no significant difference between these groups
349 (Fig. 4).
350 Analysis of clusterin expression in archived canine spinal cord
351 The archive of DM (n =4) and control (n =4) material from a
352 previous study (Johnston et al. 2000) was further analysed by
353genotyping for the 118G>A Sod1 mutation. Material from
354cases with a pathologically confirmed diagnosis of DM and
355homozygous for the 118G>A Sod1 mutation were included
356for further analysis. Material from cases with a pathological
357confirmation of diseases other than DM and lacking evidence
358of 118G>A Sod1 mutation were excluded for further
359analysis.
360An analysis of clusterin mRNA level from selected spinal
361cord material was performed. Clusterin mRNA level,
362expressed relative to the house keeping gene cyclophilin,
363was found to be elevated in the DM group relative to the
364control group (Fig. 5a). This difference bordered on statistical
365significance (p =0.05)
366The cellular expression of clusterin was then examined in
367the spinal cord by IHC using archival cases that had been
368formalin fixed and paraffin embedded. Clusterin IHC demon-
369strated strong immunoreactivity in both control and DM cases
370and demonstrated a punctate pattern within the neuronal cy-
371toplasm (Fig. 5b). Semi-quantitative assessment using a scor-
372ing system to define the staining pattern consistently found
373that positive staining was strictly confined within neuronal
374cell bodies; however, no significant difference in staining
375intensity was detected between control and DM groups (data
376not shown).
Fig. 2 Haptoglobin levels in IE and DMCSF. a Western blot analysis of
CSF haptoglobin levels in IE (n =8) and DM (n =5). Considerable signal
intensity variations were detected between samples, and samples marked
X were considered to be unquantifiable. Samples marked C and H were
also excluded due to acute disease and heterozygosity for the Sod1
(118G>A)mutation. b Vertical scattered graph of data distribution. There
was no statistically significant difference between groups. Data presented
as median and interquartile range. std reference standard, IE idiopathic
epilepsy, DM degenerative myelopathy. Filled upright triangle repre-
sents individuals with heterozygosity for Sod1 mutation in IE group
Fig. 3 Clusterin levels in IE and DM CSF. a Western blot analysis of
CSF clusterin levels in IE (n =9) and DM (n =7). b Vertical scattered
graph of data distribution. Statistical analysis revealed a significant ele-
vation in clusterin between the IE and DM groups (p <0.001). Samples
marked C and H were excluded due to acute disease and heterozygosity
for the Sod1 (118G>A) mutation. Sample marked L was collected from
lumbar CSF and the protein value from this sample is represented as open
square in the vertical scatter graph. Data presented as median and
interquartile range. ***p <0.001; std reference standard, IE idiopathic
epilepsy, DM degenerative myelopathy. Filled upright triangle repre-
sents individuals with heterozygosity for Sod1 mutation in IE group
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377 Clusterin CSF levels in a range of spinal cord conditions
378 To determine if the high CSF clusterin levels observed in DM is
379 specific to this disorder, samples were analysed from a variety
380 of neurological conditions that routinely undergo CSF collec-
381 tion (Fig. 6). The number of cases available for this compara-
382 tive study was limited. CSF clusterin was significantly elevated
383 in DM (n =4) compared to IE (n =7; p <0.001), which was
384 consistent with the previous finding and when compared to the
385 MEN (n =8) group (p <0.05). However, a similar pattern of
386 CSF clusterin elevation was also observed in cIVDD (n =4)
387 cases (p <0.01) compared to IE cases. No significant difference
388 in CSF clusterin levels was detected between DM and cIVDD
389 groups.
390 Discussion
391 In this investigation, we sought to use CSF to identify bio-
392 markers that can differentiate DM with other neurological
393 disorders with similar clinical features, yet distinct underlying
394 aetiologies. We have identified haptoglobin and clusterin as
395 components of a protein band that appeared elevated in DM
396 compared to IE. Validation analysis found that haptoglobin
397 levels were not altered between these disease groups, yet
398 clusterin was elevated in DM CSF. However, the lack of a
399 statistically significant difference in clusterin between DM
400 and cIVDD suggests that clusterin is not a specific biomarker
401 for DM. However, it was noted however that the levels of
402 clusterin were elevated by 20 % in DM CSF compared to
403 cIVDD cases and a comparison of a larger group size is
Fig. 4 Plasma clusterin levels in control (non-neurological disorders)
and DM samples. a Western blot analysis of plasma clusterin levels in
control (n =8) and DM (n =8) cases b Plasma clusterin signals were
plotted in vertical scatter plot. Statistical analysis revealed no significant
difference. Data presented as median and interquartile range. std refer-
ence standard, Ctrl control, DM degenerative myelopathy
Fig. 5 Analysis of clusterin mRNA levels and cellular distribution in control
and DM spinal cords. a The relative signal of clusterin and cyclophilin RT-
PCR amplicons observed on ethidium bromide stained agarose gels are
shown in the top panels. The signals for clusterin mRNA were normalised
relative to cyclophilin (cyclophilin:clusterin) and shown graphically. The
statistical analysis revealed no significant difference between two groups
(exact p value=0.05); however, the mean of clusterin mRNA in the DM
group (n=4)was found to be elevated by 42% compared to the control group
(n=4). Data presented as median and interquartile range. b Clusterin immu-
nostaining in T12 spinal cord sections in a representative control andDMcase
demonstrated a dark, punctate staining pattern localised in the neuronal
cytoplasm (as marked by arrow) but not in the nucleus as seen at ×60
magnification (see top right insert). The staining intensity of clusterin in
neuronal cell bodies was assessed by a subjective scoring system, but no
significant difference was evident between control (n=4) and DM (n=5)
groups. Mkr molecular weight marker, Ctrl control, DM degenerative
myelopathy
I.N.F. Shafie et al.
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404 warranted. We are currently exploring other potential CSF
405 biomarkers to assess clusterin as a member of a panel of
406 biomarkers for specific neurological disorders.
407 In order to understand the significance of CSF clusterin with
408 regards to the disease mechanisms and also appreciate its
409 potential value as a biomarker, it is imperative that the source
410 of this protein is identified. Clusterin is a highly conserved
411 glycoprotein that is ubiquitously expressed in a wide range of
412 tissues and biological fluids (Jones and Jomary 2002). It can
413 bind a variety of ligands, giving great diversity of role for
414 clusterin in cellular activities (Calero et al. 2005). Clusterin
415 has also been proposed to act as a chaperone molecule involved
416 in the regulation of extracellular protein folding (Q2 Nuutinen et al.
417 2009;Q3 Wyatt et al. 2009), has been shown to be a target for β-
418 amyloid neurotoxicity pathways (Q4 Killick et al. 2012) and can
419 also influence the formation of extracellular B-amyloid aggre-
420 gates (Narayan et al. 2012). In addition, there is strong evidence
421 that clusterin can have a protective role during oxidative stress
422 (Calero et al. 2005;Q5 Carnevali et al. 2006), ER stress-mediated
423 apoptosis (Wang et al. 2013) and may function by facilitating
424 the clearance of misfolded proteins (Q6= Poon et al. 2002;Q7 Wyatt
425 et al. 2011). However, it remains to be established if clusterin
426 functional activity is disrupted in DM. It is possible that in DM,
427the stress associated with a mutation in the Sod1 gene is
428sufficient to trigger the up-regulation and secretion of clusterin
429into the CSF. Indeed, of particular interest is a recent report that
430clusterin is elevated in the spinal cord of a symptomatic trans-
431genic model of ALS mediated by the expression of a mutated
432human SOD1G93A gene (Zinkie et al. 2013). In addition,
433clusterin has also been widely implicated in human neurode-
434generative diseases including Alzheimer’s disease (Calero et al.
4352005), Parkinson’s disease (Sasaki et al. 2002) and ALS
436(Grewal et al. 1999). Clusterin has been found to be highly
437expressed in Alzheimer’s brain tissue (Lidstrom et al. 1998);
438however, the CSF clusterin levels described in Alzheimer’s
439patients have been inconsistent (Sihlbom et al. 2008) or
440unchanged (Lidstrom et al. 2001). The elevation of
441clusterin expression also has been reported in acute spinal
442cord injury (Klimaschewski et al. 2001).
443It remains possible that the elevation of clusterin in CSF
444could be a consequence of blood-derived clusterin being
445transported to the CSF pathways through the blood-CSF-
446barrier (Reiber and Peter 2001) (Fig. 7a). Although clusterin
447levels are robust in plasma, there was no significant difference
448between the control and DM, which diminishes the possibility
449of plasma being the source of elevated clusterin in DM CSF.
Fig. 6 The comparative analysis of clusterin CSF in various neurological
disorders. a Clusterin signals obtained from Western blot analyses. b
Signals were quantified and shown graphically. Statistical analysis found
that clusterin was significantly elevated in DM (n =4) and cIVDD (n =4)
compared to IE (n =7) (DM vs. IE, p <0.001; cIVDD vs. IE, p <0.01) and
meningitis (n=8) (DM vs. meningitis, p <0.05; cIVDD vs. meningitis,
p >0.05). There was no significant difference in CSF clusterin between
DM and cIVDD. Samples marked X were excluded from the statistical
analysis. The sample marked L was collected from the lumbar cistern and
the protein value from this sample is represented as open square in the
vertical scatter graph. Data presented as median and interquartile range.
*p <0.05, **p <0.01, ***p<0.001; std reference standard, IE idiopathic
epilepsy, DM , degenerative myelopathy, MEN meningoencephalitis,
cIVDD chronic intervertebral disc disease. Filled upright triangle
represents individuals with heterozygosity for Sod1 mutation in con-
trol groups
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450 Interestingly, clusterin elevation in plasma has been reported in
451 Alzheimer’s disease (Nilselid et al. 2006; Schrijvers et al. 2011),
452 there are however no reports describing the plasma status of
453 clusterin in ALS.
454 It is tempting to speculate that elevated CSF clusterin may be
455 derived from CNS parenchyma and indeed we observed a raised
456 level of clusterinmRNA in spinal cord fromDMcases. There are
457 several reports of an elevated mRNA clusterin level that corre-
458 lates with an increase in protein abundance (Lidstrom et al. 1998;
459Grewal et al. 1999). Due to a current lack of tissue from IVDD
460cases, the basis for elevated CSF clusterin in IVDD has not yet
461been explored. Interestingly, a 40 % elevation in frontal cortex
462clusterin mRNA has been reported in sporadic ALS cases rela-
463tive to controls (Grewal et al. 1999). Similarly, in situ
464hybridisation also demonstrated that clusterin mRNA was in-
465creased in the anterior horn of the spinal cord grey matter in
466sporadic ALS patients, a region of the spinal cord that is severely
467affected by neurodegeneration (Grewal et al. 1999). Although the
Fig. 7 The potential underlying
mechanisms leading to CSF
clusterin elevation in DM. a A
cartoon illustrating the blood,
CSF and brain interfaces. CSF
clusterin elevation may reflect
changes in the blood clusterin
levels. The protein may leave the
blood vessels and enter the CSF
pathways through the tight
junctions between the ependymal
cells of the choroid plexus. b
Compartment model of CSF and
spinal cord parenchyma
interfaces. Increased clusterin
mRNA expression with a
concomitant increase of clusterin
(CLU) distribution in DM motor
neurons may lead to an elevation
in CSF clusterin. The potential
mechanism involves the
movement of clusterin from
motor neurons or potentially
astrocytes into the subarachnoid
space via the Virchow–Robin
spaces. Clusterin is subsequently
disseminated throughout the CSF
pathway
I.N.F. Shafie et al.
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468 comparison of clusterin staining intensity by IHC between archi-
469 val control and DM groups found no significant difference, it is
470 possible that the rate and/or quantity of clusterin secretion is the
471 significant cellular event. Clusterin may be secreted by motor
472 neurons (Zinkie et al. 2013), but it is has also been shown that
473 astrocytes/reactive astrocytes can secrete clusterin and may con-
474 tribute to CSF levels (Cordero-Llana et al. 2011; Zinkie et al.
475 2013), given that gliosis is a consistent pathological feature of
476 DM (Johnston et al. 2000).
477 The movement of molecules between the spinal cord pa-
478 renchyma and CSF is complex and remains speculative
479 (Brodbelt and Stoodley 2007). There is evidence of a potential
480 CSF flow into the spinal cord parenchyma through the
481 Virchow–Robin space, and conversely from the parenchyma
482 into the CSF (Stoodley et al. 1996). Since clusterin is a
483 secreted protein, it would be expected to accumulate in the
484 extracellular milieu, and this may provide an explanation for
485 how clusterin frommotor neurons can accumulate in the CSF.
486 This proposal is summarised in Fig. 7b.
487 Conclusion
488 Clusterin is elevated in the CSF of chronic spinal cord disorders
489 of the dog compared to meningitis, which is a neuroin-
490 flammatory disorder (MEN), and idiopathic epilepsy.
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